Please ensure Javascript is enabled for purposes of website accessibility

Dynavax Technologies Corporation's Stock Bolts Higher on Positive Clinical Update

By George Budwell - Jan 7, 2016 at 9:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Heplisav, Dynavax's hepatitis B vaccine candidate, met its co-primary endpoints in a late-stage study.

Source: Wikimedia Commons

What: Dynavax Technologies Corporation (DVAX 3.79%) gained more than 31% in pre-market trading this morning after the company announced that its experimental hepatitis B vaccine candidate, Heplisav-B, met its co-primary endpoints in a late-stage study. Specifically, Heplisav didn't trigger any major concerns on the safety front, according to an independent panel of experts from the Mayo Clinic. The vaccine also provided statistically superior seroprotection in diabetes patients, when compared to those receiving GlaxoSmithKline's (GSK -0.56%) Engerix-B in the active comparator arm. 

So what: Dynavax was extremely close to garnering a regulatory approval from the FDA for Heplisav a little over two years ago. However, the agency decided to reject the vaccine at that time, and instead, requested a large safety study prior to another review due to some reviewers questioning the vaccine's likelihood of inducing rare but serious side effects like Wegener's Granulomatosis or Tolosa Hunt syndrome. According to today's press release, there were no cases of either of these serious adverse events observed in this large trial, which enrolled more than 10,000 patients. 

Now what: Dynavax now plans on resubmitting the vaccine's regulatory application to the FDA before the end of the first-quarter of 2016. If the company gets a shortened review cycle, as it hopes, Heplisav could be on the market by the fourth quarter of this year.

The key issue to understand is that Heplisav could grab a major chunk of the market away from approved vaccines such as Glaxo's Engerix-B, given that it offers superior seroprotection with fewer doses in a wide diversity of patients -- including hard-to-treat patients such as those with diabetes. As such, it's not unreasonable to think that Heplisav could indeed generate peak sales in the area of $700 million to $800 million within the next decade. Regardless, Heplisav could turn out to be an incredible value driver for a company that presently sports a market cap south of $1 billion, making this small-cap biotech stock worth a deeper dive by risk-tolerant investors. 

 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$17.28 (3.79%) $0.63
GSK Stock Quote
GSK
GSK
$40.34 (-0.56%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.